Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 2022. Download the PDF
Summary of the Study
This phase 2 trial evaluated whether adding atezolizumab, an anti–PD-L1 immune checkpoint inhibitor, to FOLFOXIRI plus bevacizumab improves outcomes in patients with previously untreated metastatic colorectal cancer (mCRC).
218 patients were randomized (1:2) to receive:
- FOLFOXIRI + bevacizumab (control)
- FOLFOXIRI + bevacizumab + atezolizumab (experimental)
Median follow-up: 19.9 months
Key Results
Median progression-free survival (PFS):
- 13.1 months in the atezolizumab group vs 11.5 months in control
- HR = 0.70, p = 0.018
Safety profile was manageable, with expected grade 3–4 toxicities (e.g., neutropenia, diarrhea)
Two treatment-related deaths occurred in the atezolizumab arm
Biomarker Insight
In-depth exploratory analysis included immunological biomarkers such as Immunoscore-IC to assess predictive value for response stratification.
In this study, Alboukadel Kassambara contributed to the statistical analysis and survival modeling, specifically evaluating the predictive value of immune biomarkers such as Immunoscore-IC in the context of clinical response to atezolizumab.
Citation
Publication: In The Lancet Oncology
Date: May 27, 2022
Type: Journal Article
PDF: Download the PDF
Scientific Contributions
Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.
